Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.88 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.88 |
| ▸ | CSF1R | P07333 | 13/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912493 | 0.97 | KCNH2 (0.83) | KCNH2SCN5ACSF1R | |
| SCHEMBL1276332 | 0.94 | KCNH2 (1.00) | KCNH2SCN5ACSF1R | |
| SCHEMBL2910954 | 0.93 | KCNH2 (0.76) | KCNH2SCN5ACSF1R | |
| SCHEMBL2907540 | 0.93 | CSF1R (0.88) | KCNH2SCN5ACSF1R | |
| SCHEMBL2904672 | 0.92 | KCNH2 (0.75) | KCNH2SCN5ACSF1R | |
| SCHEMBL2912729 | 0.92 | CSF1R (0.78) | KCNH2SCN5ACSF1R | |
| SCHEMBL2912635 | 0.92 | KCNH2 (0.75) | KCNH2SCN5ACSF1R | |
| SCHEMBL2907152 | 0.92 | KCNH2 (0.75) | KCNH2SCN5ACSF1R | |
| SCHEMBL2912110 | 0.92 | CSF1R (0.78) | KCNH2SCN5ACSF1R | |
| SCHEMBL1276327 | 0.91 | KCNH2 (0.76) | KCNH2SCN5ACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | claimed |
| JP-2011510632-A | — | — | 2011-04-07 | — | — | JP | claimed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | claimed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | claimed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | claimed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007119046-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | US | disclosed |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | disclosed |
| US-8507656-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20110044998-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | TEK, VEGFA, THPO | KCNH2 4314/4885SCN5A 4393/4885CSF1R 118/4885 |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | TEK, VEGFA, THPO | KCNH2 4314/4885SCN5A 4393/4885CSF1R 118/4885 |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | TEK, VEGFA, THPO | KCNH2 4314/4885SCN5A 4393/4885CSF1R 118/4885 |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | KCNH2 3655/4885SCN5A 2645/4885CSF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.